Stockscreener 앱 받기
3.70
1.33%
-0.05
전일 마감가:
$3.75
열려 있는:
$3.7
하루 거래량:
29,352
Relative Volume:
0.45
시가총액:
$23.04M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.2967
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
+3.64%
1개월 성능:
-12.74%
6개월 성능:
-44.78%
1년 성능:
-47.20%
1일 변동 폭
$3.50
$3.7927
1주일 범위
$3.50
$5.03
52주 변동 폭
$2.92
$11.20
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
KALA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.665 | 23.04M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.74 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.25 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.21 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.28 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Geode Capital Management LLC Has $426,000 Stake in Sidus Space, Inc. (NASDAQ:SIDU) - Defense World
Geode Capital Management LLC Boosts Holdings in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Wix.com Ltd [WIX] Insider Activity: An Update for Investors - knoxdaily.com
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
Recent Insider Activity Could Benefit Insperity Inc (NSP) - knoxdaily.com
Analyzing Kala Bio Inc (KALA) After Recent Trading Activity - knoxdaily.com
International Business Machines Corp [IBM] Stock sold by Insider Thomas Robert David for $6.72 million - knoxdaily.com
Aurora Cannabis Inc [ACB] Investment Guide: What You Need to Know - knoxdaily.com
Insider Sale Alert: Angi Inc [ANGI] – Is it Time to sell? - knoxdaily.com
Kala Bio Inc (KALA) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
Kala Bio Inc (KALA) Stock: A Year of Market Fluctuations - investchronicle.com
Piper Sandler gives a Neutral recommendation for RxSight Inc (RXST) - knoxdaily.com
Oppenheimer maintains Kala Bio stock Outperform with $15 target By Investing.com - Investing.com Canada
Kala Bio announces executive retention bonuses - Investing.com Australia
KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com - Investing.com South Africa
Kala Bio announces executive retention bonuses By Investing.com - Investing.com South Africa
Kala Pharmaceuticals Announces Executive Retention Agreements - TipRanks
KALA stock touches 52-week low at $3.4 amid market challenges - Investing.com
Dynatrace, Inc. (NYSE:DT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Darling Ingredients Inc. (NYSE:DAR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Financial Lowers Bank of New York Mellon (NYSE:BK) Price Target to $90.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA) - Defense World
Kala Pharmaceuticals stock hits 52-week low at $4.05 - Investing.com India
Kala Pharmaceuticals stock hits 52-week low at $4.05 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Kala Bio, target at $15 By Investing.com - Investing.com Canada
Kala Bio Inc Reports Q4 2024 Earnings: EPS Misses Estimate at -2 - GuruFocus
Simply Good Foods (SMPL) Expected to Announce Earnings on Wednesday - The AM Reporter
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock - Investing.com Australia
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock By Investing.com - Investing.com UK
KALA BIO: Q4 Earnings Snapshot - Huron Daily Tribune
KALA BIO Advances Eye Disease Therapies with New Funding - TipRanks
KALA BIO Inc. (KALA) reports earnings - Quartz
KALA BIO, Inc. SEC 10-K Report - TradingView
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
KALA BIO (KALA) Projected to Post Quarterly Earnings on Friday - Defense World
KALA BIO Inc expected to post a loss of $2.28 a shareEarnings Preview - TradingView
Comprehensive Insights of the Global Acute Ocular Pain Market: Key Drivers, Trends, Growth Opportunities, a... - WhaTech
KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday - Defense World
PG’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Kala Bio appoints new interim CEO amid leadership shuffle - MSN
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - TradingView
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - The Manila Times
What Will KALA BIO Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
칼라 파마슈티컬스 주식 (KALA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brazzell Romulus K | SEE REMARKS |
Jan 06 '25 |
Sale |
7.63 |
2,446 |
18,663 |
92,418 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jan 06 '25 |
Sale |
7.63 |
5,779 |
44,094 |
280,076 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 06 '25 |
Sale |
7.63 |
1,706 |
13,017 |
68,581 |
0.52%
0.52%
자본화:
|
볼륨(24시간):